Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):317-26. doi: 10.1016/j.ijrobp.2011.06.1985. Epub 2011 Nov 19.

Abstract

Purpose: Desmoplastic small round cell tumor (DSCRT) is an uncommon pediatric tumor with a poor prognosis. Aggressive multimodality therapy is the current treatment approach; however. treatment toxicity is of concern. We report our results with whole abdominopelvic intensity-modulated radiation therapy (WAP-IMRT) as a component of multimodality therapy for DSCRT at a single institution.

Materials/methods: Medical records of all patients with DSCRT who received WAP-IMRT as part of definitive treatment at MD Anderson (2006-2010) were identified and reviewed.

Results: Eight patients with DSRCT received WAP-IMRT with a median follow-up of 15.2 months. All patients received multiple courses of chemotherapy followed by surgical debulking of intra-abdominal disease; seven also had intraoperative hyperthermic cisplatin. WAP-IMRT was delivered to a total dose of 30 Gy postoperatively; four patients received a simultaneous boost (6-10 Gy) to sites of gross residual disease. Seven patients received concurrent chemotherapy during WAP-IMRT. No Radiation Therapy Oncology Group Grade 4 nausea, vomiting, or diarrhea occurred during RT. Red-cell transfusions were given to two patients to maintain hemoglobin levels >10 g/dL. Grade 4 cytopenia requiring growth factor support occurred in only one patient; no other significant cytopenias were noted. WAP-IMRT resulted in 25% lower radiation doses to the lumbosacral vertebral bodies and pelvic bones than conventional RT plans. The median time to local or distant failure after WAP-IMRT was 8.73 months in seven patients. One patient who had completed RT 20 months before the last follow-up remains alive without evidence of disease. Five patients (63%) experienced treatment failure in the abdomen. Distant failure occurred in three patients (37.5%).

Conclusions: WAP-IMRT with concurrent radiosensitizing chemotherapy was well tolerated after aggressive surgery for DSCRT. Enhanced bone sparing with IMRT probably accounts for the low hematologic toxicity (vs. conventional WAP-RT). This modality should be considered as an additional local-regional control option for DSRCT.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Abdominal Neoplasms / drug therapy
  • Abdominal Neoplasms / radiotherapy*
  • Abdominal Neoplasms / surgery
  • Adolescent
  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab
  • Camptothecin / administration & dosage
  • Camptothecin / analogs & derivatives
  • Child
  • Child, Preschool
  • Cisplatin / therapeutic use
  • Combined Modality Therapy / methods
  • Cyclophosphamide / administration & dosage
  • Dacarbazine / administration & dosage
  • Dacarbazine / analogs & derivatives
  • Desmoplastic Small Round Cell Tumor / drug therapy
  • Desmoplastic Small Round Cell Tumor / radiotherapy*
  • Desmoplastic Small Round Cell Tumor / surgery
  • Erythrocyte Transfusion / methods
  • Feasibility Studies
  • Humans
  • Hyperthermia, Induced / methods
  • Interferons / administration & dosage
  • Irinotecan
  • Liver Neoplasms / radiotherapy
  • Liver Neoplasms / secondary
  • Male
  • Pelvic Neoplasms / drug therapy
  • Pelvic Neoplasms / radiotherapy
  • Pelvic Neoplasms / surgery
  • Peritoneal Neoplasms / radiotherapy
  • Peritoneal Neoplasms / secondary
  • Peritoneal Neoplasms / surgery
  • Radiation-Sensitizing Agents / therapeutic use
  • Radiotherapy Dosage
  • Radiotherapy Planning, Computer-Assisted / methods
  • Radiotherapy, Intensity-Modulated / adverse effects
  • Radiotherapy, Intensity-Modulated / methods*
  • Retrospective Studies
  • Temozolomide
  • Thrombocytopenia / etiology
  • Vinblastine / administration & dosage
  • Vinblastine / analogs & derivatives
  • Vinorelbine
  • Young Adult

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Radiation-Sensitizing Agents
  • Bevacizumab
  • Vinblastine
  • Irinotecan
  • Dacarbazine
  • Cyclophosphamide
  • Interferons
  • Cisplatin
  • Vinorelbine
  • Camptothecin
  • Temozolomide